Monashee Investment Management LLC Decreases Holdings in Roivant Sciences Ltd. (NASDAQ:ROIV)

Monashee Investment Management LLC cut its holdings in shares of Roivant Sciences Ltd. (NASDAQ:ROIVFree Report) by 36.4% during the 4th quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 350,000 shares of the company’s stock after selling 200,000 shares during the quarter. Roivant Sciences accounts for approximately 0.7% of Monashee Investment Management LLC’s holdings, making the stock its 15th biggest holding. Monashee Investment Management LLC’s holdings in Roivant Sciences were worth $3,930,000 at the end of the most recent quarter.

Several other large investors have also recently made changes to their positions in the business. Mirabella Financial Services LLP raised its stake in shares of Roivant Sciences by 4.1% during the third quarter. Mirabella Financial Services LLP now owns 34,583 shares of the company’s stock worth $404,000 after acquiring an additional 1,362 shares in the last quarter. Allspring Global Investments Holdings LLC increased its stake in shares of Roivant Sciences by 42.6% in the fourth quarter. Allspring Global Investments Holdings LLC now owns 5,385 shares of the company’s stock worth $60,000 after buying an additional 1,608 shares during the period. VELA Investment Management LLC increased its stake in shares of Roivant Sciences by 8.8% in the fourth quarter. VELA Investment Management LLC now owns 32,386 shares of the company’s stock worth $364,000 after buying an additional 2,621 shares during the period. FNY Investment Advisers LLC purchased a new position in shares of Roivant Sciences in the fourth quarter worth $33,000. Finally, Headlands Technologies LLC purchased a new position in shares of Roivant Sciences in the fourth quarter worth $36,000. 64.76% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

ROIV has been the topic of several analyst reports. Truist Financial reaffirmed a “buy” rating and issued a $23.00 target price on shares of Roivant Sciences in a research note on Monday, March 25th. Wolfe Research began coverage on shares of Roivant Sciences in a report on Thursday, February 15th. They issued an “outperform” rating and a $17.00 price target on the stock. Deutsche Bank Aktiengesellschaft lifted their price target on shares of Roivant Sciences from $14.00 to $15.00 and gave the company a “buy” rating in a report on Wednesday, April 3rd. HC Wainwright reiterated a “buy” rating and issued a $18.00 price target on shares of Roivant Sciences in a report on Monday, April 22nd. Finally, The Goldman Sachs Group lifted their price target on shares of Roivant Sciences from $16.00 to $18.00 and gave the company a “buy” rating in a report on Wednesday, April 3rd. One equities research analyst has rated the stock with a hold rating and nine have issued a buy rating to the company. According to data from MarketBeat.com, the stock presently has an average rating of “Moderate Buy” and an average price target of $16.90.

Read Our Latest Stock Analysis on ROIV

Roivant Sciences Stock Down 0.9 %

Shares of ROIV stock traded down $0.10 during mid-day trading on Wednesday, reaching $10.73. 9,579,197 shares of the company’s stock traded hands, compared to its average volume of 6,170,623. Roivant Sciences Ltd. has a 12 month low of $8.24 and a 12 month high of $13.24. The company has a market cap of $8.65 billion, a P/E ratio of 2.10 and a beta of 1.30. The company has a quick ratio of 27.79, a current ratio of 27.79 and a debt-to-equity ratio of 0.06. The company’s 50-day moving average price is $10.97 and its 200-day moving average price is $10.69.

About Roivant Sciences

(Free Report)

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.

Further Reading

Want to see what other hedge funds are holding ROIV? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Roivant Sciences Ltd. (NASDAQ:ROIVFree Report).

Institutional Ownership by Quarter for Roivant Sciences (NASDAQ:ROIV)

Receive News & Ratings for Roivant Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Roivant Sciences and related companies with MarketBeat.com's FREE daily email newsletter.